Which Peptides Are Staying Restricted in 2026 (Melanotan II, GHRP-2, GHRP-6, and More)
Not every peptide is getting good news this year. While headlines have focused on the peptides coming back into legal reach, far fewer people are asking the other half of the question: peptides still restricted 2026, and why. If you have been following the FDA's compounding overhaul, you already know that fourteen peptides are on track to return to Category 1. What often gets buried in that story is that five peptides are expected to stay right where they are, on the restricted Category 2 list, and understanding why matters just as much for your research decisions.This guide breaks down exactly which peptides are staying restricted in 2026, the safety reasoning behind each one, and what it means for researchers who want reliable, well documented compounds without wading through confusing regulatory noise.
A Quick Recap: How We Got Here
Back in September 2023, the FDA placed nineteen peptides on its Category 2 bulk drug substances list. That designation flagged each one as carrying safety concerns serious enough to pull them out of routine compounding pharmacy production. The reasons varied by compound but generally centered on immunogenicity risk, manufacturing impurities, and a lack of large scale human safety data.
In February 2026, HHS Secretary Robert F. Kennedy Jr. announced that around fourteen of those nineteen peptides were expected to move back to Category 1, restoring a legal compounding pathway under physician prescription. That was welcome news for compounds like BPC 157, TB 500, and CJC 1295. But roughly five peptides did not make that list, and they are not expected to move anytime soon.
Peptides Still Restricted 2026: The List and the Reasoning
Here is the current picture based on FDA notices and regulatory reporting through mid 2026.
Melanotan II. This one draws the most safety scrutiny by far. Melanotan II is linked to melanocyte stimulation, which raises theoretical concerns about melanoma risk in people who are already prone to skin changes. Cardiovascular effects have also been flagged. It is scheduled for a later PCAC review before the end of February 2027, not the July 2026 hearing.
GHRP-2 and GHRP-6. Both are growth hormone releasing peptides with a more complicated side effect profile than newer alternatives. Regulators point to cortisol and prolactin elevation as ongoing concerns, and GHRP-6 in particular is associated with strong appetite stimulation that complicates its safety picture.
Cathelicidin, also called LL-37. This antimicrobial peptide simply does not have enough human safety data behind it yet. Limited clinical evidence keeps it in a holding pattern.
PEG-MGF. The pegylated version of mechano growth factor has similarly thin clinical evidence, which keeps it out of the group headed back to Category 1.
A sixth compound, Dihexa acetate, is also grouped with this batch for the later 2027 review cycle. And CJC 1295 remains genuinely disputed among reporting sources, with some grouping it back into Category 1 and others flagging its DAC variant for continued scrutiny due to cardiac related reports.
Why This Distinction Actually Matters for Researchers
It is easy to see one FDA headline and assume the entire peptide category got a green light. That assumption is exactly where problems start. Category 1 status does not mean FDA approval, and it never applies evenly across every compound in the conversation. Compounds staying on Category 2 face continued restriction specifically because the safety data has not caught up yet, not because regulators forgot about them.
For anyone conducting research, this distinction should shape sourcing decisions directly. A peptide with genuine safety flags deserves extra caution regardless of what a marketplace listing claims. Reliable batch documentation becomes even more important for compounds sitting in this gray zone, because the margin for error is smaller when the underlying safety picture is still being written.
What This Means If You Are Sourcing Peptides Right Now
Picture a researcher scrolling through vendor listings this week. One page bundles a returning Category 1 compound next to a still restricted one, with identical pricing and identical vague sourcing claims for both. That kind of blending is common, and it is exactly the pattern that makes gray market sourcing risky. A restricted compound is not automatically unsafe for legitimate research use, but it absolutely requires more rigorous documentation, not less.
Verified research suppliers handle this correctly. They separate compounds by classification, disclose known safety considerations, and back every batch with third party lab testing so the researcher, not the vendor, controls the risk assessment.
How In Lab Peptides Approaches Restricted Status Compounds
In Lab Peptides tracks FDA classification changes closely and updates product documentation as new information becomes available. Every compound in the catalog ships strictly for laboratory research use, with a Certificate of Analysis attached to the specific batch, not a generic template reused across products. For compounds with ongoing safety questions, that documentation and transparency matters even more, and it is built into how In Lab Peptides operates across its entire product line, including BPC 157, TB 500, KPV, MOTS c, Semax, and Epitalon.
What Happens Next
The FDA has not yet published its formal updated Category list. Kennedy's February announcement signaled direction, but the Pharmacy Compounding Advisory Committee still needs to complete formal review, first at the July 23 and 24, 2026 hearing covering seven peptides, then again before the end of February 2027 for a second batch that includes Melanotan II, GHRP-2, GHRP-6, LL-37, PEG-MGF, and Dihexa acetate. Expect continued restriction on this second group unless new clinical evidence shifts the safety conversation. Researchers tracking peptides still restricted 2026 should watch that February 2027 meeting closely, since it is the next real decision point.
Frequently Asked Questions
Which peptides are staying restricted in 2026?
Melanotan II, GHRP-2, GHRP-6, LL-37, and PEG-MGF are expected to remain on the FDA's restricted Category 2 list, along with Dihexa acetate under a related later review.
Why is Melanotan II still restricted?
Regulators have flagged theoretical melanoma risk tied to melanocyte stimulation, along with cardiovascular concerns, as the primary safety issues keeping it restricted.
Are GHRP-2 and GHRP-6 dangerous?
They carry a more complex side effect profile than some newer growth hormone secretagogues, including cortisol and prolactin elevation, which is why regulators want more safety data before reclassification.
When will the FDA make a final decision on these compounds?
A second PCAC review covering Melanotan II, GHRP-2, GHRP-6, LL-37, PEG-MGF, and Dihexa acetate is scheduled before the end of February 2027.
Does restricted status mean a peptide cannot be sold at all?
No. Restricted status affects licensed compounding pharmacy production for prescription use. Research use only sourcing through verified suppliers remains a separate track, provided documentation and lab research standards are followed closely.
Conclusion
The peptides still restricted 2026 conversation deserves just as much attention as the reclassification wins making headlines. Melanotan II, GHRP-2, GHRP-6, LL-37, and PEG-MGF remain under continued FDA scrutiny for real safety reasons, and that context should inform how researchers evaluate sourcing decisions across the board. Working with a supplier that documents batch testing and stays current on regulatory status gives researchers a clearer, more accountable path forward. In Lab Peptides maintains that standard across its full catalog, giving researchers a dependable source as this regulatory picture continues to develop.
See verified, lab tested research peptides at In Lab Peptides
For laboratory research use only. Not for human consumption. Products sold by In Lab Peptides are intended solely for in vitro laboratory research and are not intended for use as drugs, cosmetics, medical devices, or foods. Information in this article is for educational purposes and does not constitute medical or legal advice.